Dr. Furman on The Diminishing Role of FCR in CLL (chronic lymphocytic leukemia)

As we're getting ready to head to ASH this week, we wanted to post in response to a query that was posted originally on the CLLSLL io group forum. Dr. Richard Furman is their medical advisor and his response really puts the comparison of a therapy that has existed for decades with a therapy that is less than a decade old. You can read my commentary and the text from Dr. Furman's post https://cllsociety.org/2017/12/one-mans-opinion-fcr-vs-ibrutinib/.

We'll be going night and day at ASH and plan to post while we are there. Stay tuned.